The weight loss drug industry is in full expansion mode in 2023, with huge implications for consumers, the weight-loss sector, and for the big beverage and food brands who may take a hit if dieters take a hard pass on that slice of pizza or that 32-ounce soda.
"We forecast U.S. sales for the GLP-1 category to exceed $100 billion in annual sales over time, split roughly 50/50 in diabetes and obesity,” said JP Morgan analyst Nicholas Rosato in a new research note s reported by The Wall Street Journal.” Our global market estimate is $140 billion by 2032.”Who’s running The Gap? With no CEO, retailer hurtles toward crisis
Wherever the GLP-1 weight loss sector lands in value, one side effect investors may have wondered about – the impact on food and drink companies that depend on salty snacks and sugary drinks for revenues – may be justified but with some interesting caveats. Some food and beverage retailers may escape the weight loss drug frenzy, mostly due to savvy product management that began years ago., for example, is “relatively more insulated” from consumer diet choices given that 80% of its beverage sales are overseas and that the vast majority of its top beverages have sugar-free options, JP Morgan stated. Another long-time consumer beverage company, Keurig Dr.